NEROFE

An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
18 patients (estimated)
Sponsors
Immune System Key Ltd
Collaborators
Sylvester Comprehensive Cancer Center (Main)
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1595
NCT Identifier
NCT04365179

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.